PHASE I PHASE II PHASE III APPROVED INDICATIONS TYK2 Inhibitor (2) --Autoimmune Disease TLR 7/8 Antagonist --Autoimmune Disease S1P1 Agonist --Autoimmune Disease IL-2 Agonist --Autoimmune Disease MK2 --Autoimmune Disease Branebrutinib --Rheumatoid Arthritis --Sjögren's Disease --Systemic Lupus Erythematosus TYK2 Inhibitor --Crohn's Disease --Lupus Nephritis --Psoriatic Arthritis --Systemic Lupus Erythematosus --Ulcerative Colitis Iberdomide( CELMoD ) --Systemic Lupus Erythematosus Anti-IL-13 --Eosinophilic Esophagitis ORENCIA --Idiopathic Inflammatory Myopathy NULOJIX --Switch from Calcineurin Inhibitor Renal Transplant TYK2 Inhibitor --Psoriasis Ozanimod --Crohn's Disease --Relapsing Multiple Sclerosis --Ulcerative Colitis ORENCIA --Active Polyarticular JIA --Early Rheumatoid Arthritis --JIA Intravenous --JIA Subcutaneous --Psoriatic Arthritis --RA Auto injector --RA Intravenous --RA Subcutaneous NULOJIX --De Novo Renal Transplant PHASE I PHASE II PHASE III APPROVED INDICATIONS Factor XIa Inhibitor $^{ª}$ (2)  --Thrombotic Disorders FPR-2 Agonist --Heart Failure Relaxin --Heart Failure ELIQUIS ª --Pediatric Heart Disease Nitroxyl Donor --Heart Failure Factor XIa Inhibitor ª --Thrombotic Disorders ELIQUIS ª --Stroke Prevention in Atrial Fibrillation --Venous Thromboembolism Prevention Orthopedic Surgery --Venous Thromboembolism Treatment CARDIOVASCULAR IMMUNOLOGY FIBROTIC DISEASES PHASE I PHASE II LPA$_{1}$ Antagonist --Pulmonary Fibrosis HSP47 ª --Fibrosis Pegbelfermin --Non-alcoholic Steatohepatitis JNK Inhibitor --Idiopathic Pulmonary Fibrosis --Non-Alcoholic Steatohepatitis Note: Above pipeline excludes clinical collaborations ª Development Partnership:  OPDIVO, YERVOY , Relatlimab, EP4:  Ono (our collaboration with Ono also includes other early stage compounds); EMPLICITI :  AbbVie;  Bempegaldesleukin:  Nektar;  Cabiralizumab:  Five Prime Therapeutics, Inc.;  Cabozantinib:  Exelixis, Inc.; ELIQUIS:  Pfizer; Factor XIa Inhibitor:  Janssen Pharmaceuticals, Inc.;  HSP47:  Nitto Denko Corporation;  CD3XCD33, GEMoaB CD3xPSCA, GEM333:  GeMoaB Monoclonals GmbH;  bb21217, ide-cel:  bluebird bio, Inc.;  REBLOZYL :  Acceleron Pharma Inc.;  IDHIFA,  MAT2A:  Agios Pharmaceuticals, Inc.;  AHR:  Ikena Oncology ^ Trial(s) exploring various combinations # Partner-run study 10